Cargando…

Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma

SIMPLE SUMMARY: Beta glucans, complex polysaccharides, can prime leukocyte dectin-1 and CR3-receptors and enhance anti-tumor cytotoxicity of monoclonal antibodies. In a phase I study (clinicaltrials.gov NCT00492167), we treated patients with intravenous 3F8 (fixed dose of 10 mg/m(2)/day × 10 days) a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cardenas, Fiorella Iglesias, Mauguen, Audrey, Cheung, Irene Y., Kramer, Kim, Kushner, Brian H., Ragupathi, Govind, Cheung, Nai-Kong V., Modak, Shakeel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699451/ https://www.ncbi.nlm.nih.gov/pubmed/34944886 http://dx.doi.org/10.3390/cancers13246265

Ejemplares similares

Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma
por: Modak, Shakeel, et al.
Publicado: (2013)

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-G(D2) immunotherapy and isotretinoin
por: Kushner, Brian H., et al.
Publicado: (2015)

MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-G(D2) immunotherapy
por: Kushner, Brian H., et al.
Publicado: (2017)

Targets and Antibody Formats for Immunotherapy of Neuroblastoma
por: Park, Jeong A., et al.
Publicado: (2020)

Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells
por: Yankelevich, Maxim, et al.
Publicado: (2023)

Skeletal muscle metastases in neuroblastoma share common progenitors with primary tumor and biologically resemble stage MS disease
por: Fong, Christina, et al.
Publicado: (2023)

Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
por: Chan, Godfrey Chi-Fung, et al.
Publicado: (2022)

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
por: Park, Jeong A., et al.
Publicado: (2020)

GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
por: Paret, Claudia, et al.
Publicado: (2022)

Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2
por: Larrosa, Cristina, et al.
Publicado: (2023)

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models
por: Stip, Marjolein C, et al.
Publicado: (2023)

Structure Based Refinement of a Humanized Monoclonal Antibody That Targets Tumor Antigen Disialoganglioside GD2
por: Ahmed, Mahiuddin, et al.
Publicado: (2014)

Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy
por: Liu, Xiaoming, et al.
Publicado: (2022)

Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo
por: Cheung, Nai-Kong V., et al.
Publicado: (2012)

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
por: Blom, Thomas, et al.
Publicado: (2021)

Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma
por: Yu, Eun Young, et al.
Publicado: (2019)

Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma
por: Cabral, Jennifer, et al.
Publicado: (2022)

In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors
por: Ahmed, Mahiuddin, et al.
Publicado: (2013)

Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma
por: Lavarino, Cinzia, et al.
Publicado: (2009)

Promise and Challenges of T Cell Immunotherapy for Osteosarcoma
por: Park, Jeong A, et al.
Publicado: (2023)

Immunotherapy of Childhood Sarcomas
por: Roberts, Stephen S., et al.
Publicado: (2015)

Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
por: Mora, Jaume, et al.
Publicado: (2021)

Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma
por: Aiken, Taylor J, et al.
Publicado: (2022)

Correction to: Multidisciplinary Clinical Care in the Management of Patients Receiving Anti‑GD2 Immunotherapy for High‑Risk Neuroblastoma
por: Cabral, Jennifer, et al.
Publicado: (2023)

Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells
por: Yu, Eun Young, et al.
Publicado: (2022)

Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine
por: Sun, Weili, et al.
Publicado: (2012)

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2017)

Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor
por: Espinosa-Cotton, Madelyn, et al.
Publicado: (2021)

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy
por: Santich, Brian H., et al.
Publicado: (2020)

Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins
Publicado: (1986)

Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis
por: Tas, Michelle L., et al.
Publicado: (2021)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2023)

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
por: Kroesen, Michiel, et al.
Publicado: (2016)

Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors
por: Cheng, Ming, et al.
Publicado: (2016)

Generation and Characterization of a Human/Mouse Chimeric GD(2)-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma
por: Eger, Christin, et al.
Publicado: (2016)

The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies
por: Mora, Jaume, et al.
Publicado: (2020)

The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1
por: Pilgrim, Adeiye A., et al.
Publicado: (2023)

Yeast β-Glucans as Fish Immunomodulators: A Review
por: Machuca, Cristian, et al.
Publicado: (2022)

Immune-enhancing effect of water-soluble beta-glucan derived from enzymatic hydrolysis of yeast glucan
por: Xin, Yingji, et al.
Publicado: (2022)

Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice
por: Zobel, Michael John, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pq1ep5k46abuetiudaff6ul9l2